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SUMMARY 
Thyrotoxicosis as a clinical entity has varied aetiologies. Accurate distinction of the underlying aetiology is im-
portant to guide therapy. Clinical findings are not always accurate in identifying the underlying aetiology. There is 
considerable overlap between the various aetiologies when using serum T3/T4 ratio. Although ultrasound is widely 
available and has reasonable sensitivity, it is operator dependent and misses many cases of early Grave's disease. 
99mTc scintigraphy is a simple and accurate modality for assessing the functional status of the thyroid gland and 
delineating the aetiology of thyrotoxicosis. This paper seeks to inform on the use of thyroid scintigraphy in the man-
agement of benign thyroid disorders. 
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INTRODUCTION 
The thyroid gland, a small but important endocrine or-
gan, which is usually located in the anterior neck, func-
tions to synthesise, store and secrete the thyroid hor-
mones thyroxine and tri-iodothyronine. Thyroid hor-
mones are essential for metabolism and act to increase 
oxygen consumption and basal metabolic rate.1,2 Sarfo-
Kantanka et al have reported that thyroid disorders are 
the second leading cause of endocrine morbidity in cen-
tral Ghana with hyperthyroidism accounting for 9.2% of 
all cases seen in their endocrine service.3 The same au-
thors have reported that toxic multinodular disease is 
more common than thyrotoxicosis from diffuse goitre in 
Ghana.4 In this paper, we aim to highlight the essential 
role of thyroid scintigraphy in the management of be-
nign thyroid disease and alert clinicians in Ghana to the 
availability of this resource.  
 
The physiologic basis for thyroid scintigraphy  
Anatomic imaging modalities such as ultrasonography 
or computed tomography (CT) provide information on 
the architectural structure of the thyroid gland. Ultraso-
nography is a cost-effective, non-invasive, portable, and 
safe imaging modality in the evaluation of thyrotoxico-
sis for detection of non-palpable thyroid cancers that 
may elude identification on physical examination and 
guide selection of nodules for fine needle aspiration and 
biopsy.5-8 The scintigraphic appearance however reflects 
the functional state of the entire thyroid gland as well as 
the functional status of any nodule (low uptake vs high 
uptake or same uptake as rest of the thyroid gland) 
which may have been identified by physical examina-
tion or on anatomic imaging modalities such as ultraso-
nography or computed tomography.9 On thyroid scintig-
raphy, the entire gland may have high uptake of tracer 
reflecting hyper-function of the gland (eg Grave’s dis-
ease as shown in Figure 1 or toxic nodular goitre as 
shown in Figure 2 and Figure 3) or have low uptake of 




Figure 1 30-year-old female diagnosed with hyperthyroidism 
referred for ablation. TSH < 0.01mmol/l, FT4 = 17.3pmol/ml, 
FT3 = 7.0pmol/ml. Scan showed marked homogeneous in-
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Figure 2 76-year-old female, known with hyperthyroidism 
and been on carbimazole for 6 years. TSH < 0.01mmol/l. Thy-
roid scan showed a TMNG as demonstrated by the bulky thy-
roid gland with increased inhomogeneous uptake of tracer and 
a large cold nodule in the left lobe. This nodule was confirmed 
on ultrasound guided FNA to be non-malignant. She received 
RAI treatment with 30mCi I-131 post FNA. 
 
However, nodules within the thyroid gland may exhibit 
uptake which differs from the remainder of the gland. 
For instance, in a patient with toxic multinodular goitre 
there may be a particular nodule with low tracer uptake 
(‘cold’ nodule) relative to other nodules in the gland but 
the entire gland will have high measured uptake (this is 
the situation of a hypo-functioning or cold nodule with-
in the setting of a toxic multi-nodular gland as demon-
strated in Figure 2). Conversely, there may be a domi-
nant hyper-functioning or ‘hot’ nodule in a patient with 




Figure 3 38-year-old female hyperthyroid patient on carbi-
mazole.  Her laboratory tests showed TSH = 0.02mmol/l, FT4 
= 11.27pmol/l. Scan findings revealed a toxic solitary nodule 
in the left thyroid lobe with suppression of uptake in the re-
mainder of the gland. 
 
The discipline of Nuclear Medicine has long had an 
essential role in the diagnosis and management of thy-
roid disorders. The Society of Nuclear Medicine and 
Molecular Imaging10,11 has issued guidelines for the 
performance of thyroid scintigraphy.  
 
The American Thyroid Association (ATA) and the 
American Association of Clinical Endocrinologists 
(AACE) have also issued management guidelines for 
thyrotoxicosis and other causes of hyperthyroidism.12 
 
These guidelines10,12 all detail the essential role of nu-
clear medicine/ thyroid scintigraphy in the management 
of benign thyroid disorders/ hyperthyroidism.  
The applications of thyroid scintigraphy include: 
• Evaluation of the general structure of the thyroid 
gland (e.g. nodular or diffuse enlargement) relative 
to its function. This may be useful in the differen-
tial diagnosis of hyperthyroidism, i.e. distinguish-
ing Graves’ disease from toxic nodular goitre.  
• Correlation of thyroid palpation with scintigraphic 
findings to determine the degree of function in a 
nodule that is palpable or found incidentally at a 
non-nuclear imaging procedure 
• Evaluation of the underlying aetiology of congeni-
tal hypothyroidism (total agenesis or hemiagenesis, 
dyshormonogenesis, incomplete thyroid descent) 
• Location of ectopic thyroid tissue (e.g., lingual, 
incomplete thyroid descent) and evaluation of a 
neck or substernal mass to confirm that a substernal 
mass is functioning thyroid tissue. 
• Differentiation of thyroiditis (i.e. viral, autoim-
mune) and factitious hyperthyroidism from Graves’ 
disease and other forms of hyperthyroidism. 
• Selection of thyrotoxic patients that qualify for ra-
dioactive iodine ablation therapy: Patients with 
high tracer uptake on thyroid scintigraphy are po-
tential candidates for ablation with radioiodine. In 
such patients, radioactive iodine uptake studies also 
can be used in estimating dose of I-131 for therapy 
if using the calculated dose regime. 
 
The recommended radiopharmaceuticals for thyroid 
scintigraphy are Technetium 99m pertechnetate (99mTc 
pertechnetate) and iodine -123 (123I).  Radioiodine up-
take (RAIU) measures the percentage of administered 
radioiodine that is concentrated into thyroid tissue after 
a fixed interval, typically 24 hours. A technetium uptake 
measures the percentage of administered technetium 
that is trapped by the thyroid after a fixed interval, usu-
ally 20 minutes.99mTc pertechnetate has a similar size 
and charge as iodide. It is taken up in the same manner 
via active transport mechanisms by the sodium iodide 
symporter (NIS) located in the basolateral membrane of 
the thyroid follicular cells which enables the thyroid 
gland to concentrate iodide by a factor of 20 – 40 times 
greater than its plasma levels.13-15 Unlike iodide howev-
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Apart from the thyroid gland, NIS is also expressed on 
choroid plexus, salivary glands, gastric mucosa, lactat-
ing mammary glands and ciliary body of eyes. Techne-
tium 99m pertechnetate is readily available from a Mo-
lybdenum-99/ Tc-99m generator which is usually avail-
able within all nuclear medicine departments. It is cheap 
and allows for imaging to be completed within a shorter 
time. Iodine-123 (I-123) on the other hand is cyclotron 
produced and must be pre-ordered from a distributor. 
Iodine-123 has an advantage in the identification of 
discordant nodules – nodules which appear warm on 
pertechnetate images but have decreased uptake or ap-
pear cold on I-123 imaging. Such discordant nodules 
have the capacity to trap pertechnetate but cannot or-
ganify iodine and are therefore regarded as true cold 
nodules with a higher risk of malignancy.2,9 At our cen-
tre, 99mTc sodium pertechnetate is used for thyroid scin-
tigraphy and we recommend biopsy for histologic corre-
lation of all ‘cold’ nodules and those with suspicious 
features on ultrasonography.  
 
Thyroid scintigraphy in differential diagnosis of thy-
rotoxicosis 
In thyrotoxicosis, the identification of the specific un-
derlying aetiology is useful in guiding the formulation 
of a therapy plan. Grave’s disease is a stimulation-
induced thyrotoxicosis while thyroiditis is a destruction-
induced thyrotoxicosis. Hyperthyroidism associated 
with normal to elevated radioactive iodine uptake (see 
Table 1) as occurs in Grave’s disease, toxic adenoma or 
toxic multinodular goitre, may be treated with antithy-
roid drugs, radioactive iodine therapy, and thyroidecto-
my.  
 
Table 1 Aetiologies of thyrotoxicosis and uptake of 
tracer on thyroid scintigraphy 
Elevated/ normal uptake Low/ near absent uptake  
Grave’s disease Painless thyroiditis 
Toxic adenoma Subacute/ deQuervain’s thyroiditis 
Toxic multinodular goitre Factitious/ ingestion of thyroxine 
TSH producing pituitary 
adenoma 
Amiodarone induced thyroiditis 
 
Treatment options for thyroiditis (low radioactive iodine 
uptake) induced thyrotoxicosis include beta (β) blockers 
to relieve symptoms and glucocorticoids to relieve in-
flammatory effects, if present.  
 
A radioactive iodine uptake and scan should be per-
formed when the cause of a patient’s thyrotoxicosis 
cannot be definitively determined by history and physi-
cal examination.12,17,18 Treating painless thyroiditis as if 
it were Grave’s disease would be completely inappro-
priate.12,17 Painful subacute thyroiditis is caused by viral 
infection and is characterized by fever and thyroid pain 
and this usually distinguishes this entity.  
 
However, the clinical presentation alone may not accu-
rately resolve differentiation of the aetiology of thyro-
toxicosis.  
The symptoms of painless thyroiditis can mimic those 
of early onset or recurrence of Grave’s disease, and this 
may lead to a mistreatment. The characteristic Grave’s 
ophthalmopathy, dermopathy and thyroid acropachy 
may not be present in the earlier stages of the disease.19 
Occasionally, Grave’s disease may co-exist with thy-
roiditis and may develop following the complete remis-
sion of Grave’s disease, and painless thyroiditis can be 
followed by Grave’s disease.20-23  
 
Diagnostic testing is essential to ascertain the aetiology 
of thyrotoxicosis if the diagnosis is not apparent based 
on the clinical presentation and initial biochemical eval-
uation. The choice is often dependent on available ex-
pertise and resources. Available tools to ascertain the 
underlying aetiology of thyrotoxicosis include ultraso-
nography to assess thyroidal blood flow, radioactive 
iodine uptake (RAIU)/ thyroid scintigraphy and meas-
urement of Thyrotropin receptor antibody 
(TRAb).8,12,18,24-29  
 
Thyroid ultrasound is a cheap, convenient, non-invasive 
and sensitive technique for assessing the underlying 
aetiology of thyrotoxicosis. In Grave’s disease, sonog-
raphy has a reported high sensitivity of 95% compared 
to 97% for nuclear scintigraphy.25  some authors suggest 
that ultrasound with colour doppler evaluation should be 
performed as first step in all hyperthyroid patients, and 
that scintigraphic examination should be limited only to 
the uncommon cases, where physician's observation, 
laboratory assays and/or ultrasound are not diagnostic.25 
Doppler ultrasound can be used to quantify thyroid vas-
cularity and has been reported useful in distinguishing 
Grave’s disease from destructive thyroiditis.30-32  
 
Thyrotoxicosis due to Grave’s disease is reported to be 
associated with increased peak systolic blood velocity 
through the inferior thyroidal artery whereas low flow is 
seen in destructive thyroiditis.30 European thyroid ex-
perts consider ultrasonography as the primary imaging 
modality for thyrotoxicosis because of its ready availa-
bility, convenience and ease of use24 but this opinion is 
not shared by experts in the United States of America.12 
 
The ratio of free T3 to free T4 helps to differentiate 
Grave’s disease from destruction induced thyrotoxico-
sis. The serum free T3 is considerably higher in Grave’s 
disease rather than thyroiditis.33 Sriphrapradang et al34 
reported that a serum free T3 to free T4 ratio of greater 
than 4.4 also distinguishes Grave’s disease from thy-
roiditis with a sensitivity of 47% and a specificity of 
92%. Other authors reported the FT3/FT4 ratios of pa-
tients with painless thyroiditis overlapped with those of 
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was useful for differentiating between the two disorders 
when the FT4 values were high.35 
 
TRAb measurements may be negative in 5-10% of 
Grave’s disease patients while some patients with thy-
roiditis may have positive TRAb assays.26,36,37 It has 
been recommended that a radioactive iodine uptake and 
scan be performed when the cause of a patient’s thyro-
toxicosis cannot be definitively determined by history 
and physical examination.12,17  
 
Thyroid scintigraphy with radioiodine uptake measure-
ment (RAIU) is the most reliable modality for distin-
guishing Grave’s disease from thyroiditis.6,8,12,27-29,38 
The American Thyroid Association and American As-
sociation of Clinical Endocrinologists guidelines from 
2011 suggest an approach that recommends measure-
ment of serum TRAb levels when measurement of radi-
oactive iodine uptake or thyroid scintigraphy is not 
available or contraindicated.12 Other authors however 
endorse using TRAb to identify cases of Grave’s disease 
and disagree with this diagnostic restriction on the use 
of TRAb assays.24,39 Yamashita et al have reported that 
the more frequent use of TRAb assays rather than scin-
tigraphy in Japan compared with the United States and 
Korea is related to multiple factors including the relative 
shortage of nuclear medicine facilities.40 A 123I or 99mTc 
pertechnetate scan should be obtained when the clinical 
presentation suggests a Toxic adenoma (TA) or toxic 
multinodular goitre (TMNG).18 
 
Biochemical and scintigraphic changes in thyroiditis 
The thyroiditis includes Hashimoto’s thyroiditis, painful 
subacute thyroiditis, painless sporadic thyroiditis and 
painless postpartum thyroiditis. Hashimoto’s thyroiditis, 
painless sporadic thyroiditis and painless postpartum 
thyroiditis are all associated with autoimmune phenom-
ena.41 The thyroidites are associated with destruction of 
the thyroid gland with release of preformed thyroid 
hormone into the circulation results in a transient hyper-
thyroidism. As the glandular stores of thyroid hormone 
are depleted, the clinical course of disease is character-
ised by periods of hypothyroidism and euthyroidism.  
 
The first biochemical change in inflammatory thyroidi-
tis before the onset of thyrotoxicosis is an increase in 
the serum concentration of thyroglobulin. Similar to 
other forms of thyrotoxicosis, the serum concentration 
of thyroid stimulating hormone (TSH) is suppressed, 
and concentrations of total and free triiodothyronine 
(T3) and thyroxine (T4) are elevated with serum T4 
concentrations proportionally higher than T3 concentra-
tions, reflecting the ratio of stored hormone in the thy-
roid gland (whereas in Graves’ disease and in toxic 
nodular goitre, T3 is preferentially elevated).  
 
These changes in hormonal levels are associated with 
corresponding changes in radiopharmaceutical uptake 
on scintigraphy. During the early stages of thyroiditis, 
the serum T4 levels are elevated and TSH is suppressed. 
This phase is associated with a low tracer uptake on 
scintigraphy. In the mid phase of thyroiditis, serum T4 
is low while TSH and uptake on scintigraphic are high. 
Normalisation of serum TSH and T4 in the latter stages 
is associated with a normal uptake on scintigraphy.2,41  
 
Amiodarone induced thyrotoxicosis 
Amiodarone, an anti-arrhythmic drug has a high iodine 
content. Most patients on amiodarone therapy remain 
euthyroid; however, some may develop thyroid function 
anomalies which may be hypothyroidism or thyrotoxi-
cosis depending on the iodine status of the patient’s 
locale. Patients from iodine depleted areas usually get 
amiodarone induced thyrotoxicosis (AIT) while those 
living in iodine replete areas get amiodarone induced 
hypothyroidism.42,43 There are two distinct pathophysio-
logic mechanisms for AIT.  
 
While AIT type I is thought to be due to excess iodine 
mediated increased production of thyroid hormone, AIT 
type II is the result of a destructive thyroiditis. It is im-
portant to distinguish the two types of AIT because their 
therapy is different. Type I AIT may show normal or 
increased tracer uptake on scintigraphy but type II AIT 
is associated with low tracer uptake. Colour flow Dop-
pler may show increased flow/ hypervascularity in cases 
of type I AIT and absence of hypervascularity in type II 
AIT.42,44 
 
Thyroid scintigraphy in assessment of function of a 
thyroid nodule 
Correlation of thyroid palpation with scintigraphic find-
ings is important to determine the degree of function in 
a nodule that is palpable or found incidentally during 
routine physical examination or at a non-nuclear imag-
ing procedure. Compared to ultrasound, thyroid scintig-
raphy has a lower sensitivity for diagnosing thyroid 
nodules24,25 due to the limitation posed by the intrinsic 
resolution of the gamma camera used for nuclear medi-
cine imaging. Most gamma cameras cannot pick- up 
nodules below 1 cm in size.2  
 
Several guidelines12,18 and other authors7,9,24,28 recom-
mend the use of thyroid scintigraphy to assess the func-
tion of clinically palpable nodules or those found at 
non-nuclear medicine imaging procedures such as ultra-
sonography. If a nodule is composed of cells that do not 
make thyroid hormone (do not absorb iodine/ non-
functioning), then it will appear "cold" on scintigraphy 
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A nodule that is producing too much hormone will ap-
pear "hot’’ (see figure 3).  Functional assessment of a 
thyroid nodule is important as 15 – 20% of cold nodules 
are malignant2 with this percentage increasing further in 
patients who are younger, male, have cervical lymphad-
enopathy, history of radiation to the neck and family 
history of thyroid abnormalities. The incidence of ma-
lignancy in a cold nodule in multinodular goitres is 
however very low (less than 5%) compared to gland 
with a single nodule. A functioning nodule however is 
less likely to be malignant with a 1% - 5% chance of the 
hot nodule being malignant.2  
 
Ultrasound guided fine needle aspiration (FNA) and 
cytology is the most accurate test for detecting malig-
nancy in a thyroid nodule. However, FNA is invasive 
and may produce indeterminate results in up to 25% of 
cases45. Scintigraphy assessment of nodules reduces the 
potential number of un-needed biopsies and guides pa-
tient management. 
 
Evaluation of the aetiology of congenital hypothy-
roidism (total agenesis or hemiagenesis, dyshormon-
ogenesis, incomplete thyroid descent)  
In countries where screening programmes exist, chil-
dren with congenital hypothyroidism are usually identi-
fied in the neonatal period utilising sensitive TSH as-
says. Thyroid scintigraphy helps to identify the aetiolo-
gy or abnormality responsible for the congenital hypo-
thyroidism. Scintigraphy can identify agenesis (absence 
of uptake), hypoplasia of a gland in situ (with or without 
hemithyroid), a normal or large gland in situ with or 
without abnormally high levels of uptake (Figure 4), 
and an ectopic thyroid at any point along the pathway of 
the normal embryological descent from the foramen 
caecum at the base of the tongue to the thyroid carti-
lage.46,47 Combining scintigraphy and thyroid ultrasound 
in an individual patient helps to improve diagnostic ac-
curacy.46 
 
Thyroid scintigraphy prior to radioiodine ablation 
In addition to aiding the differentiation of the various 
aetiologies of hyperthyroidism, thyroid scintigraphy and 
radioiodine uptake (RAIU) is indicated prior to treat-
ment with iodine – 131. Thyrotoxic patients with high 
tracer uptake on thyroid scintigraphy are potential can-
didates for ablation with radioiodine and the dose ad-
ministered for the treatment may be determined using 
empiric dosing or a calculated dose.  
 
If the calculated or estimated dosing approach is to be 
used, the administered dose is determined using multi-
ple parameters which includes the radioiodine uptake 
measurement. Even in empiric dosing schemes, patients 
with multinodular goitre tend to be given higher doses 
than those with Grave’s disease.  
 
Scintigraphic imaging directly guides iodine – 131 
treatment planning to maximise therapeutic benefit 
while minimising adverse effects.  
 
Nuclear medicine imaging and therapy in managing 
benign and malignant thyroid disease is established and 





Figure 4 5-year-old boy diagnosed with primary hypo-
thyroidism with 3 months history of thyroxine ingestion. 
Thyroid scan shows a markedly enlarged thyroid gland 
with increased inhomogenous uptake of the tracer. The 
increased tracer uptake in the presence of hypothyroid-
ism is an indication of intact Na/I symporters respond-
ing to stimulation by high TSH levels as occurs in thy-
roid dyshormonogenesis. 
 
The experience from the National Nuclear Medicine 
centre in Ghana 
There is a nuclear medicine service located within the 
National Radiotherapy and Nuclear Medicine Centre at 
the Korle-Bu Teaching Hospital. At the centre, thyroid 
scintigraphy is performed using Technetium -99m sodi-
um pertechnetate. The images included in this paper 
illustrate the utility of thyroid scintigraphy in the man-
agement of benign thyroid disorders in Ghana. With a 
second nuclear medicine centre poised to be established 
at the Komfo Anokye Teaching Hospital in Kumasi, this 
invaluable resource will become even more accessible 
to clinicians and many more Ghanaians. A total of 155 
scans for benign thyroid disorders were performed dur-
ing the period June 2014 to June 2017.  
 
Nuclear medicine imaging and therapy have established 
roles in managing benign thyroid disease and is the 
most successful example of molecular radiotheranostics. 
In Ghana, the utility of thyroid scintigraphy is hampered 
by the limited availability of nuclear medicine facilities.  
 
With plans to open new nuclear medicine facilities and 
increasing physician awareness, there will be opportuni-
ties to further leverage thyroid scintigraphy and enhance 
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CONCLUSION 
Thyroid scintigraphy has numerous roles in the man-
agement of benign thyroid disorders.  
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